Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Arbil Acikalin; Emine Bagir; Merve Inceman; Mutlu Deger; Seyda Erdogan

doi:10.5114/pjp.2020.103711

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2020
vol. 71

Send email

Copy url:

abstract:

Original paper

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Arbil Acikalin

¹

,

Emine Bagir

¹

,

Merve Inceman

¹

,

Mutlu Deger

²

,

Seyda Erdogan

¹

Cukurova University Medical School, Department of Pathology, Saricam, Adana, Turkey
Cukurova University Medical School, Department of Urology, Saricam, Adana, Turkey

Pol J Pathol 2020; 71 (4): 307-313

DOI: https://doi.org/10.5114/pjp.2020.103711

Online publish date: 2021/02/22

View full text Get citation

PlumX metrics:

Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been approved for urothelial carcinoma, but their use for small-cell carcinoma (SmCC) of the urinary bladder is unclear. Thus, we analyzed PD-1 and PD-L1 expression in NECs, particularly in SmCC of the urinary bladder. We used PD-1 antibody and two different biomarkers for PD-L1 antibodies, Ventana SP263 (Ventana Medical Systems, Inc.) and AM26531AF-N (Acris Antibodies GmbH). Among the 12 SmCC cases, 16.7% stained positive on immune cells for PD-1 and 33.0% for PD-L1. PD-L1 positivity on tumor cells was 25.0% of SmCC cases. The overall survival was shorter in PD-L1-positive patients compared with PD-L1-negative patients (15.4 months vs. 27.6 months). Large cell carcinoma (n = 1) was strongly and diffusely stained with PD-L1, and this case had the longest survival (68 months) in the group. Immune checkpoint inhibitors may be an alternative treatment option in SmCC of the urinary bladder. Furthermore, the absence of PD-L1 may be a good prognostic parameter.

keywords:

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder

Arbil Acikalin 1 , Emine Bagir 1 , Merve Inceman 1 , Mutlu Deger 2 , Seyda Erdogan 1

immune checkpoint, PD-1, PD-L1, small-cell carcinoma, urinary bladder

Arbil Acikalin

¹

,

Emine Bagir

¹

,

Merve Inceman

¹

,

Mutlu Deger

²

,

Seyda Erdogan

¹